8 research outputs found
Reporting of Randomized Controlled Trials in Hodgkin Lymphoma in Biomedical Journals
Background: Randomized controlled trials (RCTs) are the best tool to evaluate the effectiveness of clinical interventions. The Consolidated Standards for Reporting Trials (CONSORT) statement was introduced in 1996 to improve reporting of RCTs. We aimed to determine the extent of ambiguity and reporting quality as assessed by adherence to the CONSORT statement in published reports of RCTs involving patients with Hodgkin lymphoma from 1966 through 2002. Methods: We analyzed 242 published full-text reports of RCTs in patients with Hodgkin lymphoma. Quality of reporting was assessed using a 14-item questionnaire based on the CONSORT checklist. Reporting was studied in two pre-CONSORT periods (1966-1988 and 1989-1995) and one post-CONSORT period (1996-2002). Results: Only six of the 14 items were addressed in 75% or more of the studies in all three time periods. Most items that are necessary to assess the methodologic quality of a study were reported by fewer than 20% of the studies. Improvements over time were seen for some items, including the description of statistics methods used, reporting of primary research outcomes, performance of power calculations, method of randomization and concealment allocation, and having performed intention-to-treat analysis. Conclusions: Despite recent improvements, reporting levels of CONSORT items in RCTs involving patients with Hodgkin lymphoma remain unsatisfactory. Further concerted action by journal editors, learned societies, and medical schools is necessary to make authors even more aware of the need to improve the reporting RCTs in medical journals to allow assessment of validity of published clinical researc
Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals
BACKGROUND: Randomized controlled trials (RCTs) are the best tool to evaluate the effectiveness of clinical interventions. The Consolidated Standards for Reporting Trials (CONSORT) statement was introduced in 1996 to improve reporting of RCTs. We aimed to determine the extent of ambiguity and reporting quality as assessed by adherence to the CONSORT statement in published reports of RCTs involving patients with Hodgkin lymphoma from 1966 through 2002. METHODS: We analyzed 242 published full-text reports of RCTs in patients with Hodgkin lymphoma. Quality of reporting was assessed using a 14-item questionnaire based on the CONSORT checklist. Reporting was studied in two pre-CONSORT periods (1966-1988 and 1989-1995) and one post-CONSORT period (1996-2002). RESULTS: Only six of the 14 items were addressed in 75% or more of the studies in all three time periods. Most items that are necessary to assess the methodologic quality of a study were reported by fewer than 20% of the studies. Improvements over time were seen for some items, including the description of statistics methods used, reporting of primary research outcomes, performance of power calculations, method of randomization and concealment allocation, and having performed intention-to-treat analysis. CONCLUSIONS: Despite recent improvements, reporting levels of CONSORT items in RCTs involving patients with Hodgkin lymphoma remain unsatisfactory. Further concerted action by journal editors, learned societies, and medical schools is necessary to make authors even more aware of the need to improve the reporting RCTs in medical journals to allow assessment of validity of published clinical research
Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published inmedical journals (Review)
Background: An overwhelming body of evidence stating that the completeness of reporting of randomised controlled trials (RCTs) is not optimal
has accrued over time. In the mid-1990s, in response to these concerns, an international group of clinical trialists, statisticians,
epidemiologists, and biomedical journal editors developed the CONsolidated Standards Of Reporting Trials (CONSORT) Statement.
The CONSORT Statement, most recently updated in March 2010, is an evidence-based minimum set of recommendations including
a checklist and flow diagram for reporting RCTs and is intended to facilitate the complete and transparent reporting of trials and aid
their critical appraisal and interpretation. In 2006, a systematic review of eight studies evaluating the “effectiveness of CONSORT in
improving reporting quality in journals” was published.
Objectives: To update the earlier systematic review assessing whether journal endorsement of the 1996 and 2001 CONSORT checklists influences
the completeness of reporting of RCTs published in medical journals.
Search methods: We conducted electronic searches, known item searching, and reference list scans to identify reports of evaluations assessing the
completeness of reporting of RCTs. The electronic search strategy was developed inMEDLINE and tailored to EMBASE.We searched
the Cochrane Methodology Register and the Cochrane Database of Systematic Reviews using the Wiley interface. We searched the
Science Citation Index, Social Science Citation Index, and Arts and Humanities Citation Index through the ISI Web of Knowledge
interface. We conducted all searches to identify reports published between January 2005 and March 2010, inclusive.
Selection criteria: In addition to studies identified in the original systematic review on this topic, comparative studies evaluating the completeness of
reporting of RCTs in any of the following comparison groups were eligible for inclusion in this review: 1) Completeness of reporting
of RCTs published in journals that have and have not endorsed the CONSORT Statement; 2) Completeness of reporting of RCTs
published in CONSORT-endorsing journals before and after endorsement; or 3) Completeness of reporting of RCTs before and after
the publication of the CONSORT Statement (1996 or 2001). We used a broad definition of CONSORT endorsement that includes
any of the following: (a) requirement or recommendation in journal’s ’Instructions to Authors’ to follow CONSORT guidelines; (b)
journal editorial statement endorsing the CONSORT Statement; or (c) editorial requirement for authors to submit a CONSORT
checklist and/or flow diagram with their manuscript. We contacted authors of evaluations reporting data that could be included in
any comparison group(s), but not presented as such in the published report and asked them to provide additional data in order to
determine eligibility of their evaluation. Evaluations were not excluded due to language of publication or validity assessment.
Data collection and analysis: We completed screening and data extraction using standardised electronic forms, where conflicts, reasons for exclusion, and level
of agreement were all automatically and centrally managed in web-based management software, DistillerSR®. One of two authors
extracted general characteristics of included evaluations and all data were verified by a second author. Data describing completeness of
reporting were extracted by one author using a pre-specified form; a 10%random sample of evaluations was verified by a second author.
Any discrepancies were discussed by both authors; we made no modifications to the extracted data. Validity assessments of included
evaluations were conducted by one author and independently verified by one of three authors. We resolved all conflicts by consensus.
For each comparison we collected data on 27 outcomes: 22 items of the CONSORT 2001 checklist, plus four items relating to the
reporting of blinding, and one item of aggregate CONSORT scores. Where reported, we extracted and qualitatively synthesised data
on the methodological quality of RCTs, by scale or score.
Main results: Fifty-three publications reporting 50 evaluations were included. The total number of RCTs assessed within evaluations was 16,604
(median per evaluation 123 (interquartile range (IQR) 77 to 226) published in a median of six (IQR 3 to 26) journals. Characteristics of
the included RCT populations were variable, resulting in heterogeneity between included evaluations. Validity assessments of included
studies resulted in largely unclear judgements. The included evaluations are not RCTs and less than 8% (4/53) of the evaluations
reported adjusting for potential confounding factors.
Twenty-five of 27 outcomes assessing completeness of reporting in RCTs appeared to favour CONSORT-endorsing journals over
non-endorsers, of which five were statistically significant. ’Allocation concealment’ resulted in the largest effect, with risk ratio (RR)
1.81 (99% confidence interval (CI) 1.25 to 2.61), suggesting that 81% more RCTs published in CONSORT-endorsing journals
adequately describe allocation concealment compared to those published in non-endorsing journals. Allocation concealment was
reported adequately in 45% (393/876) of RCTs in CONSORT-endorsing journals and in 22% (329/1520) of RCTs in non-endorsing
journals. Other outcomes with results that were significant include: scientific rationale and background in the ’Introduction’ (RR 1.07,
99% CI 1.01 to 1.14); ’sample size’ (RR 1.61, 99% CI 1.13 to 2.29); method used for ’sequence generation’ (RR 1.59, 99% CI 1.38
to 1.84); and an aggregate score over reported CONSORT items, ’total sum score’ (standardised mean difference (SMD) 0.68 (99%
CI 0.38 to 0.98)).
Authors’ conclusions: Evidence has accumulated to suggest that the reporting of RCTs remains sub-optimal. This review updates a previous systematic review
of eight evaluations. The findings of this review are similar to those from the original review and demonstrate that, despite the general
inadequacies of reporting of RCTs, journal endorsement of the CONSORT Statement may beneficially influence the completeness
of reporting of trials published in medical journals. Future prospective studies are needed to explore the influenc